958 Stock Overview
Pharmiva AB (publ) engages in the research and development of medical products in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Pharmiva AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.048 |
| 52 Week High | SEK 0.15 |
| 52 Week Low | SEK 0.041 |
| Beta | 1.56 |
| 11 Month Change | -27.84% |
| 3 Month Change | -13.62% |
| 1 Year Change | -52.51% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -95.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| 958 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 1.3% | -1.3% | 0.8% |
| 1Y | -52.5% | -17.7% | 6.1% |
Return vs Industry: 958 underperformed the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: 958 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 958 volatility | |
|---|---|
| 958 Average Weekly Movement | 14.6% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 958's share price has been volatile over the past 3 months.
Volatility Over Time: 958's weekly volatility has decreased from 21% to 15% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 5 | Anna Linton | www.pharmiva.com |
Pharmiva AB (publ) engages in the research and development of medical products in Sweden. The company offers Vernivia, an over-the-counter vaginal mousse for the treatment of bacterial vaginosis. The company was incorporated in 2015 and is headquartered in Lund, Sweden.
Pharmiva AB (publ) Fundamentals Summary
| 958 fundamental statistics | |
|---|---|
| Market cap | €851.70k |
| Earnings (TTM) | -€1.87m |
| Revenue (TTM) | €373.05k |
2.3x
P/S Ratio-0.5x
P/E RatioIs 958 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 958 income statement (TTM) | |
|---|---|
| Revenue | SEK 4.26m |
| Cost of Revenue | SEK 1.65m |
| Gross Profit | SEK 2.61m |
| Other Expenses | SEK 24.03m |
| Earnings | -SEK 21.42m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.23 |
| Gross Margin | 61.22% |
| Net Profit Margin | -502.51% |
| Debt/Equity Ratio | 0% |
How did 958 perform over the long term?
See historical performance and comparison